Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Vivace hits high note in midstage mesothelioma trial
Vivace plans to launch a phase 3 study of potential first-in-class VT3989 in mesothelioma in the first half of 2026.
Darren Incorvaia
Oct 19, 2025 10:30am
Cabaletta's CAR-T wipes out B cells with no preconditioning
Oct 10, 2025 11:11am
Ionis rare disease candidate ekes out phase 3 win
Sep 22, 2025 10:46am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
Cytokinetics’ ph. 3 cardio win sends stock soaring
Sep 2, 2025 2:05pm
Vedanta's live bacteria cocktail fails phase 2 colitis trial
Aug 13, 2025 1:48pm
